Empagliflozin vs Ertugliflozin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline

Empagliflozin · Jardiance

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01131676 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).

Next expected readout: November 2026 · NCT05057806 (registry estimate)

Reported efficacy

Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)

Result source: NCT01131676

Ertugliflozin · Steglatro

Marketed by Merck & Co. and partners

Approved in Type 2 Diabetessmall molecule
Reliable signal

NCT01986881 · Phase 3 · completed

This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.

Next expected readout: January 2028 · NCT07621380 (registry estimate)

Reported efficacy

Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)

Result source: NCT01986881

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmpagliflozinErtugliflozin
HbA1c, change-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825
Body weight, change (kg)-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
-2.3 vs -0.4−1.9 vs placebo15 mg · wk 18 · n 2746NCT01986881
43 other results
  • -2.8 vs -0.4 15 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.8 vs -1.3 15 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
HbA1c below 7%34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
28.2% vs 15.5%+12.7 vs placebo15 mg · wk 18 · n 2520NCT01986881
43 other results
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 20% vs 16.5% 15 mg · wk 260 · n 529 · Phase 3 · secondary NCT01986881
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
Fasting plasma glucose, change-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
-1.9 vs -0.9−1 vs placebo15 mg · wk 18 · n 2747NCT01986881
63 other results
  • -1.6 vs -0.5 15 mg · wk 52 · n 2328 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825
3-point MACE (% with event)10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
—Not posted · NCT03717194

HbA1c, change

Empagliflozin
-0.7% vs -0.2%−0.5 vs placebo10mg · wk 24 · n 217NCT01159600
32 other results
  • -0.8% vs -0.2% 10mg · wk 24 · n 225 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 213 · Phase 3 · primary NCT01159600
  • -0.8% vs -0.2% 25mg · wk 24 · n 216 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 10 mg · wk 24 · n 72 · Phase 3 · primary NCT04233801
  • -0.7% vs 0.1% 10 mg-25 mg · wk 24 · n 78 · Phase 3 · primary NCT02182830
  • -2.8% vs -0.2% 25mg · wk 24 · n 69 · Phase 3 · primary NCT01159600
  • -2.5% vs -0.2% 25mg · wk 24 · n 101 · Phase 3 · primary NCT01159600
  • -1.1% vs -0.1% 25 mg · wk 24 · n 73 · Phase 3 · primary NCT04233801
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.9% vs 0.2% 10 mg/5 mg · wk 24 · n 182 · Phase 3 · primary NCT02453555
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -1.4% vs -1.8% 10 mg qd · wk 24 · n 156 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 12.5 mg Bid + 1000 mg Bid · wk 24 · n 159 · Phase 3 · primary NCT01719003
  • -0.2% vs 0.3% 10 mg, 25 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.4% vs -1.8% 25 mg qd · wk 24 · n 143 · Phase 3 · primary NCT01719003
  • -1.9% vs -1.8% 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · primary NCT01719003
  • -2.1% vs -1.8% 5 mg Bid + 1000 mg Bid · wk 24 · n 151 · Phase 3 · primary NCT01719003
  • -2.0% vs -1.8% 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · primary NCT01719003
  • -0.5% vs 0.3% 10 mg · wk 26 · n 39 · Phase 3 · primary NCT03429543
  • 0.1% vs 0.3% 10 mg, 10-25 mg · wk 26 · n 41 · Phase 3 · primary NCT03429543
  • -1.1% vs 0.1% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -1.1% vs -0.0% 25 mg/5 mg · wk 52 · n 126 · Phase 3 · secondary NCT02453555
  • -0.2% vs 0.1% 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -0.6% vs -0.2% 10 mg QD · wk 16 · n 213 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.2% 25 mg QD · wk 16 · n 214 · Phase 2 · primary NCT01649297
  • -0.8% vs -0.2% 12.5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
  • -0.7% vs -0.1% 10 mg · wk 52 · n 64 · Phase 4 · primary NCT04531462
  • -0.9% vs 0% 10 mg · wk 16 · n 86 · Phase 4 · primary NCT02589639
  • -1% vs 0% 25 mg · wk 16 · n 90 · Phase 4 · primary NCT02589639
  • -0.7% vs -0.2% 5 mg BID · wk 16 · n 215 · Phase 2 · primary NCT01649297
Ertugliflozin
-1.0% vs 0.2%−1.2 vs placebo15 mg · wk 26 · n 151NCT01958671
65 other results
  • -0.9% vs -0.0% 15 mg · wk 26 · n 205 · Phase 3 · primary NCT02033889
  • -0.9% vs -0.1% 15 mg · wk 26 · n 153 · Phase 3 · primary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 155 · Phase 3 · primary NCT01986855
  • -0.9% vs -0.2% 15 mg · wk 26 · n 169 · Phase 3 · primary NCT02630706
  • -0.8% vs -0.2% 15 mg · wk 18 · n 370 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.2% 5 mg · wk 18 · n 348 · Phase 3 · primary NCT01986881
  • -0.8% vs -0.6% 15 mg · wk 18 · n 54 · Phase 3 · primary NCT01986881
  • -1.0% vs -0.2% 15 mg · wk 18 · n 113 · Phase 3 · primary NCT01986881
  • -0.8% vs 0.2% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT01958671
  • -0.7% vs -0.0% 5 mg · wk 26 · n 207 · Phase 3 · primary NCT02033889
  • -0.8% vs -0.1% 5 mg · wk 26 · n 156 · Phase 3 · primary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 158 · Phase 3 · primary NCT01986855
  • -1% vs -0.2% 5 mg · wk 26 · n 170 · Phase 3 · primary NCT02630706
  • -0.9% vs -0.6% 5 mg · wk 18 · n 55 · Phase 3 · primary NCT01986881
  • -0.9% vs -0.2% 5 mg · wk 18 · n 100 · Phase 3 · primary NCT01986881
  • -1.7% vs -0.4% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · primary NCT02226003
  • -1.6% vs -0.4% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · primary NCT02226003
  • -0.6% vs 0.1% wk 24 · n 111 · Phase 3 · primary NCT04029480
  • -0.6% vs -0.7% 15 mg · wk 52 · n 440 · Phase 3 · primary NCT01999218
  • -1.1% vs -1.1% 15 mg · wk 26 · n 248 · Phase 3 · primary NCT02099110
  • -0.6% vs -0.7% 5 mg · wk 52 · n 448 · Phase 3 · primary NCT01999218
  • -1.0% vs -1.1% 5 mg · wk 26 · n 250 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · primary NCT02099110
  • -1.5% vs -1.1% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · primary NCT02099110
  • -0.7% vs -0.2% 15 mg · wk 52 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 15 mg · wk 18 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 15 mg · wk 104 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 15 mg · wk 156 · n 1574 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 15 mg · wk 208 · n 2747 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.2% 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.5% vs -0.1% 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.4% vs -0.0% 5 mg · wk 156 · n 1590 · Phase 3 · secondary NCT01986881
  • -0.2% vs 0.1% 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -0.3% vs -0.1% 15 mg · wk 260 · n 527 · Phase 3 · secondary NCT01986881
  • -0.7% vs -0.7% 5 mg · wk 52 · n 179 · Phase 3 · secondary NCT02033889
  • -0.3% vs -0.1% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -1.0% vs -0.7% 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -0.4% vs -0.3% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -0.9% vs -0.6% 15 mg · wk 104 · n 142 · Phase 3 · secondary NCT02033889
  • -0.8% vs 0.0% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -0.3% vs -0.3% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -0.5% vs 0.3% 5 mg · wk 24 · n 85 · Phase 3 · secondary NCT04029480
  • -0.6% vs -0.6% 5 mg · wk 104 · n 147 · Phase 3 · secondary NCT02033889
  • -0.2% vs 0.8% wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -0.4% vs 0.3% wk 24 · n 89 · Phase 3 · secondary NCT04029480
  • -0.1% vs 0.2% 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.3% vs 0.2% 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -0.8% vs -0.1% 5 mg · wk 12 · n 53 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 12 · n 50 · Phase 2 · primary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 12 · n 51 · Phase 2 · primary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT01059825
  • -0.8% vs -0.1% 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -0.3% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.8% vs -0.1% 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -0.7% vs -0.1% 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -0.5% vs -0.0% 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -0.2% vs 0% 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -0.6% vs -0.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.4% vs -0.0% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.1% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT01059825

Body weight, change (kg)

Empagliflozin
-2.1 vs -0.4−1.7 vs placebo10mg · wk 24 · n 217NCT01159600
18 other results
  • -2.2 vs -0.4 10mg · wk 24 · n 225 · Phase 3 · secondary NCT01159600
  • -2.5 vs -0.4 25mg · wk 24 · n 213 · Phase 3 · secondary NCT01159600
  • -2.4 vs -0.4 25mg · wk 24 · n 216 · Phase 3 · secondary NCT01159600
  • -0.8 vs -0.0 10 mg, 25 mg · wk 26 · n 48 · Phase 3 · secondary NCT03429543
  • -2.0 vs 0.0 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • -2.2 vs -1.0 10 mg-25 mg · wk 24 · n 78 · Phase 3 · secondary NCT02182830
  • -1.3 vs -0.4 25mg · wk 24 · n 69 · Phase 3 · secondary NCT01159600
  • -1.3 vs -0.4 25mg · wk 24 · n 101 · Phase 3 · secondary NCT01159600
  • -1.3 vs 0.0 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 1.3 vs -0.0 10 mg, 25 mg · wk 26 · n 4 · Phase 3 · secondary NCT03429543
  • -2.4 vs -1.3 10 mg qd · wk 24 · n 155 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.3 25 mg qd · wk 24 · n 143 · Phase 3 · secondary NCT01719003
  • -3.8 vs -1.3 12.5 mg Bid + 1000 mg Bid · wk 24 · n 160 · Phase 3 · secondary NCT01719003
  • -3.0 vs -1.3 12.5 mg Bid + 500 mg Bid · wk 24 · n 149 · Phase 3 · secondary NCT01719003
  • -3.5 vs -1.3 5 mg Bid + 1000 mg Bid · wk 24 · n 150 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.3 5 mg Bid + 500 mg Bid · wk 24 · n 155 · Phase 3 · secondary NCT01719003
Ertugliflozin
-2.3 vs -0.4−1.9 vs placebo15 mg · wk 18 · n 2746NCT01986881
43 other results
  • -2.8 vs -0.4 15 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.2 vs -0.7 15 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.0 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • -3.8 vs -1.3 15 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.4 5 mg · wk 18 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.5 vs -0.4 5 mg · wk 52 · n 2746 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.7 5 mg · wk 104 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.0 vs -1.0 5 mg · wk 156 · n 1595 · Phase 3 · secondary NCT01986881
  • -3.4 vs -1.3 5 mg · wk 208 · n 2746 · Phase 3 · secondary NCT01986881
  • -3.6 vs -1.4 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -2.9 vs -1.3 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -3.0 vs -1.3 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -3.2 vs -1.2 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -2.1 vs -0.3 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -3.4 vs 0.1 15 mg · wk 52 · n 178 · Phase 3 · secondary NCT02033889
  • -4.6 vs -1.2 15 mg · wk 260 · n 530 · Phase 3 · secondary NCT01986881
  • -1.9 vs -0.3 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -3.7 vs -1.2 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • -1.4 vs 0.5 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.2 vs -0.7 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.4 vs -0.5 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -2.8 vs -0.9 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -3.6 vs -0.2 15 mg · wk 104 · n 145 · Phase 3 · secondary NCT02033889
  • -3.2 vs -1.4 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • -3.0 vs -1.3 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -3.4 vs -1.3 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -1.3 vs 0.5 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -3.0 vs -1.2 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.8 vs -0.7 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.5 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -3.2 vs 0.1 5 mg · wk 52 · n 181 · Phase 3 · secondary NCT02033889
  • -3.5 vs -0.9 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -3.8 vs -0.2 5 mg · wk 104 · n 148 · Phase 3 · secondary NCT02033889
  • -3.0 vs -0.9 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • -2.9 vs -0.9 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • -7.4 vs -1.0 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -4.2 vs -1.0 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -3.7 vs -0.7 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -3.4 vs 0.9 15 mg · wk 52 · n 440 · Phase 3 · secondary NCT01999218
  • -2.7 vs -0.7 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -3.0 vs 0.9 5 mg · wk 52 · n 448 · Phase 3 · secondary NCT01999218
  • -2.9 vs -0.7 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.5 vs -0.7 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110

HbA1c below 7%

Empagliflozin
34.6% vs 24.5%+10.1 vs placebo10 mg, 25 mg · wk 26 · n 52NCT03429543
3 other results
  • 16.7% vs 8.2% 10 mg · wk 24 · n 72 · Phase 3 · secondary NCT04233801
  • 30.1% vs 8.2% 25 mg · wk 24 · n 73 · Phase 3 · secondary NCT04233801
  • 66.7% vs 24.5% 10 mg, 25 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
Ertugliflozin
28.2% vs 15.5%+12.7 vs placebo15 mg · wk 18 · n 2520NCT01986881
43 other results
  • 29% vs 17.4% 15 mg · wk 52 · n 2347 · Phase 3 · secondary NCT01986881
  • 23.8% vs 16.6% 15 mg · wk 104 · n 1541 · Phase 3 · secondary NCT01986881
  • 22.7% vs 16.9% 15 mg · wk 156 · n 1578 · Phase 3 · secondary NCT01986881
  • 22.7% vs 18.2% 15 mg · wk 208 · n 860 · Phase 3 · secondary NCT01986881
  • 28.4% vs 15.5% 5 mg · wk 18 · n 2544 · Phase 3 · secondary NCT01986881
  • 28.3% vs 17.4% 5 mg · wk 52 · n 2363 · Phase 3 · secondary NCT01986881
  • 23.9% vs 16.6% 5 mg · wk 104 · n 1570 · Phase 3 · secondary NCT01986881
  • 23.1% vs 16.9% 5 mg · wk 156 · n 1592 · Phase 3 · secondary NCT01986881
  • 35.8% vs 13.1% 15 mg · wk 26 · n 151 · Phase 3 · secondary NCT01958671
  • 40% vs 15.8% 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • 40.8% vs 16.2% 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • 21.1% vs 10.7% 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • 33.7% vs 19.1% 15 mg · wk 104 · n 205 · Phase 3 · secondary NCT02033889
  • 20% vs 16.5% 15 mg · wk 260 · n 529 · Phase 3 · secondary NCT01986881
  • 20.7% vs 10.7% 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • 24.9% vs 18.2% 5 mg · wk 208 · n 876 · Phase 3 · secondary NCT01986881
  • 39.9% vs 17% 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • 11.3% vs 12.1% 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • 36.6% vs 30.6% 15 mg · wk 52 · n 205 · Phase 3 · secondary NCT02033889
  • 35.3% vs 15.8% 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • 34.8% vs 30.6% 5 mg · wk 52 · n 207 · Phase 3 · secondary NCT02033889
  • 24.6% vs 19.1% 5 mg · wk 104 · n 207 · Phase 3 · secondary NCT02033889
  • 18.6% vs 16.5% 5 mg · wk 260 · n 526 · Phase 3 · secondary NCT01986881
  • 27.8% vs 25% 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • 32.7% vs 12.8% 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • 32.7% vs 13.7% 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • 28.2% vs 13.1% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT01958671
  • 32.1% vs 17% 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • 16.2% vs 12.1% 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • 38.2% vs 16.2% 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • 32.7% vs 25% 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • 37% vs 12.8% 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • 33.3% vs 13.7% 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • 31.3% vs 8.3% 15 mg + 100 mg · wk 26 · n 96 · Phase 3 · secondary NCT02226003
  • 35.7% vs 8.3% 5 mg + 100 mg · wk 26 · n 98 · Phase 3 · secondary NCT02226003
  • 31.9% vs 32.8% 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • 26.4% vs 32.8% 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • 49.2% vs 32.8% 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • 52.3% vs 32.8% 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • 42.9% vs 15.6% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT01059825
  • 36.2% vs 15.6% 25 mg · wk 12 · n 47 · Phase 2 · secondary NCT01059825
  • 38.6% vs 15.6% 10 mg · wk 12 · n 44 · Phase 2 · secondary NCT01059825
  • 44% vs 15.6% 1 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825

Fasting plasma glucose, change

Empagliflozin
-1.8 vs 0.3−2.1 vs placebo25 mg + 5 mg · wk 24 · n 109NCT01734785
11 other results
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.8 10 mg qd · wk 24 · n 154 · Phase 3 · secondary NCT01719003
  • -1.6 vs -1.8 25 mg qd · wk 24 · n 139 · Phase 3 · secondary NCT01719003
  • -2.8 vs -1.8 12.5 mg Bid + 1000 mg Bid · wk 24 · n 158 · Phase 3 · secondary NCT01719003
  • -2.4 vs -1.8 12.5 mg Bid + 500 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.6 vs -1.8 5 mg Bid + 1000 mg Bid · wk 24 · n 146 · Phase 3 · secondary NCT01719003
  • -2.5 vs -1.8 5 mg Bid + 500 mg Bid · wk 24 · n 153 · Phase 3 · secondary NCT01719003
  • -1.0 vs -0.0 10 mg QD · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.3 vs -0.0 25 mg QD · wk 16 · n 214 · Phase 2 · secondary NCT01649297
  • -1.5 vs -0.0 12.5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
  • -1.2 vs -0.0 5 mg BID · wk 16 · n 213 · Phase 2 · secondary NCT01649297
Ertugliflozin
-1.9 vs -0.9−1 vs placebo15 mg · wk 18 · n 2747NCT01986881
63 other results
  • -1.6 vs -0.5 15 mg · wk 52 · n 2328 · Phase 3 · secondary NCT01986881
  • -1.4 vs -0.2 15 mg · wk 104 · n 1536 · Phase 3 · secondary NCT01986881
  • -1.3 vs -0.2 15 mg · wk 156 · n 1567 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.9 5 mg · wk 18 · n 2745 · Phase 3 · secondary NCT01986881
  • -0.9 vs 0.2 15 mg · wk 208 · n 861 · Phase 3 · secondary NCT01986881
  • -1.6 vs -0.5 5 mg · wk 52 · n 2352 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.2 5 mg · wk 104 · n 1562 · Phase 3 · secondary NCT01986881
  • -1.1 vs -0.2 5 mg · wk 156 · n 1579 · Phase 3 · secondary NCT01986881
  • -2.2 vs -0.1 15 mg · wk 26 · n 205 · Phase 3 · secondary NCT02033889
  • -1.8 vs -0.4 15 mg · wk 18 · n 370 · Phase 3 · secondary NCT01986881
  • -0.6 vs -0.3 15 mg · wk 260 · n 524 · Phase 3 · secondary NCT01986881
  • -1.8 vs -0.1 15 mg · wk 26 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs -0.7 15 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.6 vs -0.6 15 mg · wk 104 · n 144 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.1 5 mg · wk 26 · n 207 · Phase 3 · secondary NCT02033889
  • -1.5 vs -0.4 5 mg · wk 18 · n 348 · Phase 3 · secondary NCT01986881
  • -0.8 vs 0.2 5 mg · wk 208 · n 868 · Phase 3 · secondary NCT01986881
  • -0.8 vs -0.3 5 mg · wk 260 · n 520 · Phase 3 · secondary NCT01986881
  • -2.4 vs 0.0 15 mg · wk 26 · n 152 · Phase 3 · secondary NCT01958671
  • -1.1 vs -0.3 15 mg · wk 26 · n 97 · Phase 3 · secondary NCT01986855
  • -1.9 vs -0.4 15 mg · wk 26 · n 169 · Phase 3 · secondary NCT02630706
  • -1.5 vs -0.8 15 mg · wk 18 · n 54 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 15 mg · wk 18 · n 113 · Phase 3 · secondary NCT01986881
  • -1.5 vs 0.2 15 mg · wk 52 · n 153 · Phase 3 · secondary NCT02036515
  • -1.9 vs 0.0 5 mg · wk 26 · n 155 · Phase 3 · secondary NCT01958671
  • -1.5 vs -0.1 5 mg · wk 26 · n 156 · Phase 3 · secondary NCT02036515
  • -0.7 vs -0.3 5 mg · wk 26 · n 105 · Phase 3 · secondary NCT01986855
  • -2.1 vs -0.4 5 mg · wk 26 · n 170 · Phase 3 · secondary NCT02630706
  • -1.6 vs -0.8 5 mg · wk 18 · n 55 · Phase 3 · secondary NCT01986881
  • -2.0 vs -0.3 5 mg · wk 18 · n 100 · Phase 3 · secondary NCT01986881
  • -1.2 vs -0.7 5 mg · wk 52 · n 173 · Phase 3 · secondary NCT02033889
  • -1.4 vs 0.2 5 mg · wk 52 · n 156 · Phase 3 · secondary NCT02036515
  • -1.0 vs -0.6 5 mg · wk 104 · n 143 · Phase 3 · secondary NCT02033889
  • -1.1 vs 0.5 wk 24 · n 111 · Phase 3 · secondary NCT04029480
  • -0.7 vs 1.2 wk 54 · n 111 · Phase 3 · secondary NCT04029480
  • -4.7 vs 0.8 15 mg · wk 312 · n 12 · Phase 3 · secondary NCT01986881
  • -0.1 vs 0.8 5 mg · wk 312 · n 13 · Phase 3 · secondary NCT01986881
  • -2.0 vs -1.4 15 mg · wk 26 · n 248 · Phase 3 · secondary NCT02099110
  • -2.0 vs -1.4 5 mg · wk 26 · n 250 · Phase 3 · secondary NCT02099110
  • -2.7 vs -1.4 15 mg + 100 mg · wk 26 · n 244 · Phase 3 · secondary NCT02099110
  • -2.4 vs -1.4 5 mg + 100 mg · wk 26 · n 243 · Phase 3 · secondary NCT02099110
  • -1.3 vs 0.1 5 mg · wk 12 · n 53 · Phase 2 · secondary NCT01059825
  • -1.4 vs 0.2 5 mg · wk 8 · n 53 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 5 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.3 vs 0.3 5 mg · wk 4 · n 53 · Phase 2 · secondary NCT01059825
  • -1.3 vs -0.3 5 mg · wk 2 · n 34 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.1 25 mg · wk 12 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 8 · n 50 · Phase 2 · secondary NCT01059825
  • -1.7 vs 0.2 25 mg · wk 4 · n 35 · Phase 2 · secondary NCT01096667
  • -1.5 vs 0.3 25 mg · wk 4 · n 50 · Phase 2 · secondary NCT01059825
  • -1.8 vs -0.3 25 mg · wk 2 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 25 mg · wk 2 · n 49 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.1 10 mg · wk 12 · n 51 · Phase 2 · secondary NCT01059825
  • -1.8 vs 0.2 10 mg · wk 8 · n 51 · Phase 2 · secondary NCT01059825
  • -1.6 vs 0.3 10 mg · wk 4 · n 51 · Phase 2 · secondary NCT01059825
  • -1.5 vs 0.3 10 mg · wk 2 · n 50 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.1 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT01059825
  • -1.0 vs 0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT01059825
  • -0.8 vs 0.2 1 mg · wk 4 · n 36 · Phase 2 · secondary NCT01096667
  • -0.9 vs 0.3 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT01059825
  • -0.6 vs -0.3 1 mg · wk 2 · n 35 · Phase 2 · secondary NCT01096667
  • -0.8 vs 0.3 1 mg · wk 2 · n 51 · Phase 2 · secondary NCT01059825

3-point MACE (% with event)

Empagliflozin
10.4% vs 12.1%−1.7 vs placebo10 mg · n 2345NCT01131676
2 other results
  • 10.5% vs 12.1% 25 mg · n 2342 · Phase 3 · primary NCT01131676
  • 10.5% vs 12.1% n 4687 · Phase 3 · primary NCT01131676
Ertugliflozin
—Not posted · NCT03717194
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety

Coverage. Empagliflozin: 13 of 13 rows · Ertugliflozin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmpagliflozin
Rows use multiple source trials
Ertugliflozin
Rows use multiple source trials
Ambulatory DBP
absolute change · mmHg
-6.38 vs -1.48 placebo mmHg @ 24wk10 mg-25 mga,b,c,d
NCT02182830 · Phase 3 · registry result, not featured evidence
-2.34 vs 0.77 placebo mmHg @ 4wk5 mge,a,b,c,d
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-1.5 vs 0.77 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-1.89 vs 0.77 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
Ambulatory SBP
absolute change · mmHg
-10.33 vs -1.94 placebo mmHg @ 24wk10 mg-25 mga,b,c,d
NCT02182830 · Phase 3 · registry result, not featured evidence
-3.73 vs 0.26 placebo mmHg @ 4wk5 mge,a,b,c,d
NCT01096667 · Phase 2 · registry result, not featured evidence
show 2 more doses
-3.42 vs 0.26 placebo mmHg @ 4wk25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
-2.71 vs 0.26 placebo mmHg @ 4wk1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
DBP
absolute change · mmHg
-3.37 vs -1.59 placebo mmHg @ 24wk10 mge,b,c,f
NCT04233801 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.94 vs -1.59 placebo mmHg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-0.97 vs 1.21 placebo mmHg @ 26wk15 mg + 100 mge,b,c,f
NCT02226003 · Phase 3 · combination
show 1 more dose
-0.44 vs 1.21 placebo mmHg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-19.48 vs 15.7 placebo mg @ 26wk10 mg, 25 mge,g,h
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
-18.45 vs 15.7 placebo mg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-55.36 vs -9.3 placebo mg @ 26wk15 mg + 100 mge,g,h
NCT02226003 · Phase 3 · combination
show 1 more dose
-48.25 vs -9.3 placebo mg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
GFR mL/Min 1 73m2
absolute value · mL
124 vs 132.5 placebo mL @ 4wk25 mgi,c,j
NCT02632747 · Phase 2 · registry result, not featured evidence
48.6 vs 50.1 placebo mL @ 12wki,c,j
NCT03416270 · Phase 2 · registry result, not featured evidence
HbA1c Less Than 6 5
responder rate · % of participants
21.2% (n=52) vs 9.4% (n=53) placebo @ 26wk10 mg, 25 mge,g,c
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
12.2% (n=205) vs 2.9% (n=209) placebo @ 26wk15 mge,g,c
NCT02033889 · Phase 3
show 1 more dose
8.7% (n=207) vs 2.9% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
SBP
absolute change · mmHg
-5.56 vs -1.95 placebo mmHg @ 24wk10 mge,b,c,f
NCT04233801 · Phase 3 · registry result, not featured evidence
show 1 more dose
-2.96 vs -1.95 placebo mmHg @ 24wk25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
-3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mge,b,c,f
NCT02226003 · Phase 3 · combination
show 1 more dose
-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg
NCT02226003 · Phase 3 · combination
Seated DBP
absolute change · mmHg
0.78 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mge,k,h
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
-3.2 vs 0.76 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-1.1 vs -0.72 placebo mmHg @ 26wk15 mge,k,h
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
-2.52 vs -0.72 placebo mmHg @ 26wk5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
Seated SBP
absolute change · mmHg
-0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mge,k,h
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
show 1 more dose
2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
-3.93 vs -2.22 placebo mmHg @ 26wk15 mge,k,h
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
-5.54 vs -2.22 placebo mmHg @ 26wk5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
Dropout rate
23.7%10 mgl
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
23.2%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
8%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
8.7%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
17.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
8.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
15.9%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
6.2%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
11.2%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
4.4%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
9.4%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
6.1%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
2.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.5%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
18.1%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
10.2%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
7.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5.3%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
7.7%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
12.1%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
8.6%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
6.4%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
7.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
—15 mgm
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.6%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
12%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.8%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
12.2%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
22.9%15 mg
NCT01999218 · Phase 3
24.3%5 mg
NCT01999218 · Phase 3
12.5%15 mg
NCT02099110 · Phase 3
9.6%5 mg
NCT02099110 · Phase 3
11%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
9.1%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
7.7%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
3.2%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
9%15 mg
NCT01986855 · Phase 3
8.2%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.3%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
4.1%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
0%
NCT03416270 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
7.7%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
5.1%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
39.3%
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
11.4%10 mgl
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
11.6%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.9%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
3.2%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.9%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
—10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.6%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
5.6%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.3%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
3.1%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
1.7%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
2.4%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
0%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.9%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
2.3%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
—10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
—Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
—Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
4.8%Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
—25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
5.9%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
1.8%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
—15 mgm
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
—5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.7%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.6%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%15 mg
NCT02033889 · Phase 3
0.5%5 mg
NCT02033889 · Phase 3
1.6%15 mg
NCT01999218 · Phase 3
2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
1.2%5 mg
NCT02099110 · Phase 3
0.8%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
1.2%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
0.6%15 mg
NCT02036515 · Phase 3
—15 mg
NCT02036515 · Phase 3 · combination
0.6%5 mg
NCT02036515 · Phase 3
—5 mg
NCT02036515 · Phase 3 · combination
—15 mg + 100 mg
NCT02226003 · Phase 3 · combination
—5 mg + 100 mg
NCT02226003 · Phase 3 · combination
0%15 mg
NCT01986855 · Phase 3
0.6%5 mg
NCT01986855 · Phase 3
—15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
—5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0.6%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
1.2%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
—
NCT03416270 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
—
NCT04167761 · Phase 1 · registry result, not featured evidence
—15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
—1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Serious AEs
37.4%10 mgl
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 40 more results
39%25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
4.9%10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.2%10mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
0.5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
5%25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
1.4%25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
5.4%10 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
0%25 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
12.3%10 mg
NCT04531462 · Phase 4 · registry result, not featured evidence
10.5%10 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
8.9%25 mg
NCT02589639 · Phase 4 · registry result, not featured evidence
6.3%10 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
—25 mg
NCT02589626 · Phase 4 · registry result, not featured evidence
3%25mg
NCT02589626 · Phase 4 · registry result, not featured evidence
13.7%10 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
9.6%25 mg
NCT04233801 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.7%10 mg-25 mg
NCT02182830 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0.6%10 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
1.8%25 mg qd
NCT01719003 · Phase 3 · registry result, not featured evidence
3.8%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%12.5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
3.5%12.5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg Bid + 1000 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
1.2%5 mg Bid + 500 mg Bid
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
0%10 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
0%25 mg
NCT01947855 · Phase 3 · registry result, not featured evidence
6.4%Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence
7.1%Finerenone + Empagliflozin Group
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
—Finerenone and Empagliflozin
NCT05254002 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT02632747 · Phase 2 · registry result, not featured evidence
2.3%10 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
0.9%25 mg QD
NCT01649297 · Phase 2 · registry result, not featured evidence
2.3%12.5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
3.2%5 mg BID
NCT01649297 · Phase 2 · registry result, not featured evidence
7.3%15 mgm
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 53 more results
7.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.1%15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.9%15 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
9.5%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
34.9%5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.3%5 mg
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.9%15 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.1%5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
9.8%15 mg
NCT02033889 · Phase 3
9.7%5 mg
NCT02033889 · Phase 3
7.4%15 mg
NCT01999218 · Phase 3
9.2%5 mg
NCT01999218 · Phase 3
2%15 mg
NCT02099110 · Phase 3
4.8%5 mg
NCT02099110 · Phase 3
4.9%15 mg + 100 mg
NCT02099110 · Phase 3 · combination
3.7%5 mg + 100 mg
NCT02099110 · Phase 3 · combination
—15 mg
NCT02036515 · Phase 3
2%15 mg
NCT02036515 · Phase 3 · combination
—5 mg
NCT02036515 · Phase 3
8.3%5 mg
NCT02036515 · Phase 3 · combination
3.1%15 mg + 100 mg
NCT02226003 · Phase 3 · combination
2%5 mg + 100 mg
NCT02226003 · Phase 3 · combination
19.4%15 mg
NCT01986855 · Phase 3
16.5%5 mg
NCT01986855 · Phase 3
3.8%15 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
3.2%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
0%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
4.5%5 mg
NCT04029480 · Phase 3 · registry result, not featured evidence
5.9%15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
5.3%5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
17.6%
NCT03416270 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01096667 · Phase 2 · registry result, not featured evidence
3.6%5 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
1.8%25 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT01059825 · Phase 2 · registry result, not featured evidence
0%
NCT04167761 · Phase 1 · registry result, not featured evidence
0%15 mg Oral + 100 ug Oral
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg Oral + 100 ug IV
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
0%15 mg
NCT02115347 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
—15 mg
NCT01948986 · Phase 1 · registry result, not featured evidence
0%4 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Once Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%2 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
0%1 mg Twice Daily
NCT01054300 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
10 mgl
hypoglycaemia 29.6% (placebo 29.4%)
urinary tract infection 14.5% (placebo 14.7%)
hyperglycaemia 9.3% (placebo 18.1%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 37 more results
25 mg
hypoglycaemia 28.7% (placebo 29.4%)
urinary tract infection 14.4% (placebo 14.7%)
nasopharyngitis 9.4% (placebo 9.3%)
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10mg
hypoglycaemia 15.6% (placebo 9.8%)
urinary tract infection 9.4% (placebo 6.7%)
nasopharyngitis 8% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
10mg
nasopharyngitis 5.5% (placebo 4.9%)
urinary tract infection 4.1% (placebo 6.7%)
hyperglycaemia 2.3% (placebo 12.4%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 12.9% (placebo 9.8%)
urinary tract infection 6.9% (placebo 6.7%)
nasopharyngitis 6% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
hypoglycaemia 8.9% (placebo 9.8%)
hyperglycaemia 7.9% (placebo 12.4%)
nasopharyngitis 5% (placebo 4.9%)
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7% (placebo 4.9%)
upper respiratory tract infections 4.2% (placebo 5.3%)
urinary tract infection 4.2% (placebo 6.7%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
25mg
nasopharyngitis 7.2% (placebo 4.9%)
urinary tract infection 7.2% (placebo 6.7%)
diarrhoea 5.8% (placebo 0%)
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3
10 mg
headache 16.2% (placebo 15.5%)
hypoglycaemia 16.2% (placebo 12.1%)
vitamin d deficiency 13.5% (placebo 13.8%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
25 mg
hypoglycaemia 17.2% (placebo 12.1%)
blood ketone body increased 10.3% (placebo 3.4%)
headache 10.3% (placebo 15.5%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
10 mg
constipation 10.8% (placebo 4.7%)
pyrexia 6.2% (placebo 4.7%)
nasopharyngitis 4.6% (placebo 6.3%)
NCT04531462 · Phase 4 · registry result, not featured evidence
10 mg
nasopharyngitis 34.9% (placebo 31.1%)
hypoglycaemia 27.9% (placebo 21.1%)
pollakiuria 10.5% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
25 mg
hypoglycaemia 27.8% (placebo 21.1%)
nasopharyngitis 26.7% (placebo 31.1%)
pollakiuria 10% (placebo 2.2%)
NCT02589639 · Phase 4 · registry result, not featured evidence
10 mg
viral upper respiratory tract infection 31.3%
fall 3.1%
influenza 0%
NCT02589626 · Phase 4 · registry result, not featured evidence
25mg
viral upper respiratory tract infection 33.3%
influenza 9.1%
fall 6.1%
NCT02589626 · Phase 4 · registry result, not featured evidence
10 mg
hypoglycaemia 20.5% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg
hypoglycaemia 15.1% (placebo 15.1%)
urinary tract infection 8.2% (placebo 13.7%)
hyperlipidaemia 5.5% (placebo 2.7%)
NCT04233801 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg-25 mg
lipase increased 7.5% (placebo 3.9%)
cough 6.3% (placebo 1.3%)
upper respiratory tract infection 2.5% (placebo 5.2%)
NCT02182830 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg qd
dyslipidaemia 8.7%
urinary tract infection 7%
upper respiratory tract infection 2.9%
NCT01719003 · Phase 3 · registry result, not featured evidence
25 mg qd
urinary tract infection 7.8%
dyslipidaemia 6.6%
upper respiratory tract infection 4.2%
NCT01719003 · Phase 3 · registry result, not featured evidence
12.5 mg Bid + 1000 mg Bid
diarrhoea 7.5%
dizziness 5.7%
gastritis 5.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 1000 mg Bid
urinary tract infection 10.6%
diarrhoea 7.1%
dyslipidaemia 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
12.5 mg Bid + 500 mg Bid
urinary tract infection 10%
dizziness 5.3%
diarrhoea 3.5%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 1000 mg Bid
urinary tract infection 7%
dyslipidaemia 4.7%
upper respiratory tract infection 4.7%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
5 mg Bid + 500 mg Bid
dyslipidaemia 8.9%
diarrhoea 5.3%
urinary tract infection 5.3%
NCT01719003 · Phase 3 · registry result, not featured evidence · combination
10 mg
nasopharyngitis 10% (placebo 4.8%)
anal inflammation 0% (placebo 0%)
bartholinitis 0% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
25 mg
anal inflammation 5.3% (placebo 0%)
bartholinitis 5.3% (placebo 0%)
pollakiuria 5.3% (placebo 0%)
NCT01947855 · Phase 3 · registry result, not featured evidence
nasopharyngitis 4.1%
glomerular filtration rate decreased 3.8%
hyperkalaemia 3.8%
NCT05254002 · Phase 2 · registry result, not featured evidence
hyperkalaemia 9.3%
glomerular filtration rate decreased 6.3%
diarrhoea 3.4%
NCT05254002 · Phase 2 · registry result, not featured evidence · combination
25 mg
ketosis 19.4% (placebo 3.3%)
fatigue 9.7% (placebo 0%)
headache 9.7% (placebo 10%)
NCT02632747 · Phase 2 · registry result, not featured evidence
10 mg QD
urinary tract infection 6.8% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
25 mg QD
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
12.5 mg BID
urinary tract infection 4.6% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
5 mg BID
urinary tract infection 3.7% (placebo 3.7%)
NCT01649297 · Phase 2 · registry result, not featured evidence
15 mgm
hypoglycaemia 30.3% (placebo 31.4%)
nasopharyngitis 3.5% (placebo 3.2%)
upper respiratory tract infection 2.7% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 44 more results
15 mg
hypoglycaemia 16.8% (placebo 31.4%)
nasopharyngitis 4.4% (placebo 3.2%)
dizziness 3.5% (placebo 1.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 31.1% (placebo 31.4%)
urinary tract infection 9.5% (placebo 2%)
nasopharyngitis 7.4% (placebo 3.2%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
hypoglycaemia 5.6% (placebo 31.4%)
urinary tract infection 1.9% (placebo 2%)
back pain 0% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 29% (placebo 31.4%)
dizziness 2.3% (placebo 1.2%)
upper respiratory tract infection 2.3% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 13% (placebo 31.4%)
hypertension 4% (placebo 0.6%)
hyperglycaemia 3% (placebo 1.7%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 32.2% (placebo 31.4%)
urinary tract infection 9.3% (placebo 2%)
upper respiratory tract infection 7.2% (placebo 2.6%)
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 5.5% (placebo 31.4%)
back pain 3.6% (placebo 0.6%)
hypertension 3.6% (placebo 0.6%)
NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15 mg
nasopharyngitis 7.2% (placebo 3.9%)
upper respiratory tract infection 6.6% (placebo 5.9%)
urinary tract infection 6.6% (placebo 12.4%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
5 mg
urinary tract infection 8.3% (placebo 12.4%)
vulvovaginal mycotic infection 7.7% (placebo 1.3%)
constipation 7.1% (placebo 2.6%)
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3
15 mg
upper respiratory tract infection 10.2% (placebo 15.8%)
back pain 9.8% (placebo 4.8%)
hypoglycaemia 8.8% (placebo 20.6%)
NCT02033889 · Phase 3
5 mg
upper respiratory tract infection 11.1% (placebo 15.8%)
headache 6.8% (placebo 4.8%)
hypoglycaemia 6.8% (placebo 20.6%)
NCT02033889 · Phase 3
15 mg
urinary tract infection 6.4%
hypoglycaemia 5.7%
headache 4.4%
NCT01999218 · Phase 3
5 mg
upper respiratory tract infection 6.1%
urinary tract infection 6.1%
headache 5.6%
NCT01999218 · Phase 3
15 mg
urinary tract infection 7.7%
hypoglycaemia 5.2%
nasopharyngitis 5.2%
NCT02099110 · Phase 3
5 mg
urinary tract infection 8%
hypoglycaemia 4.8%
nasopharyngitis 2.4%
NCT02099110 · Phase 3
15 mg + 100 mg
hypoglycaemia 8.2%
nasopharyngitis 4.9%
urinary tract infection 3.3%
NCT02099110 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.8%
nasopharyngitis 4.9%
hypoglycaemia 3.7%
NCT02099110 · Phase 3 · combination
15 mg
nasopharyngitis 3.9% (placebo 3.3%)
hypoglycaemia 3.3% (placebo 7.2%)
urinary tract infection 3.3% (placebo 5.2%)
NCT02036515 · Phase 3 · combination
5 mg
back pain 5.1% (placebo 3.9%)
nasopharyngitis 5.1% (placebo 3.3%)
hypoglycaemia 4.5% (placebo 7.2%)
NCT02036515 · Phase 3 · combination
15 mg + 100 mg
urinary tract infection 2.1% (placebo 1%)
hyperglycaemia 1% (placebo 6.2%)
blood glucose increased 0% (placebo 7.2%)
NCT02226003 · Phase 3 · combination
5 mg + 100 mg
urinary tract infection 5.1% (placebo 1%)
blood glucose increased 3.1% (placebo 7.2%)
hyperglycaemia 0% (placebo 6.2%)
NCT02226003 · Phase 3 · combination
15 mg
hypoglycaemia 20.6% (placebo 29.2%)
urinary tract infection 7.7% (placebo 9.7%)
upper respiratory tract infection 7.1% (placebo 4.5%)
NCT01986855 · Phase 3
5 mg
hypoglycaemia 31% (placebo 29.2%)
diarrhoea 6.3% (placebo 5.8%)
cough 5.7% (placebo 1.3%)
NCT01986855 · Phase 3
15 mg
hypoglycaemia 19.2% (placebo 12.7%)
nausea 15.4% (placebo 7.3%)
vomiting 15.4% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
upper respiratory tract infection 14.3% (placebo 10.9%)
hypoglycaemia 11.1% (placebo 12.7%)
covid-19 7.9% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 11.5% (placebo 12.7%)
nausea 7.7% (placebo 7.3%)
vomiting 7.7% (placebo 5.5%)
NCT04029480 · Phase 3 · registry result, not featured evidence
5 mg
nausea 13.6% (placebo 7.3%)
abdominal pain 9.1% (placebo 5.5%)
diarrhoea 9.1% (placebo 7.3%)
NCT04029480 · Phase 3 · registry result, not featured evidence
15 mg
hyperuricaemia 5.3% (placebo 12%)
hypoglycaemia 5.3% (placebo 1.2%)
nasopharyngitis 5.3% (placebo 6.6%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
nasopharyngitis 5.3% (placebo 6.6%)
hypoglycaemia 3.5% (placebo 1.2%)
hyperuricaemia 2.9% (placebo 12%)
NCT02630706 · Phase 3 · registry result, not featured evidence
5 mg
genital infection fungal 7.9% (placebo 0%)
athralgia 5.3% (placebo 0%)
nasopharyngitis 5.3% (placebo 0%)
NCT01096667 · Phase 2 · registry result, not featured evidence
25 mg
fatigue 5.1% (placebo 0%)
polyuria 5.1% (placebo 0%)
dizziness 2.6% (placebo 5.3%)
NCT01096667 · Phase 2 · registry result, not featured evidence
1 mg
musculoskeletal pain 5.1% (placebo 0%)
upper respiratory tract infection 2.6% (placebo 5.3%)
urinary tract infection 2.6% (placebo 2.6%)
NCT01096667 · Phase 2 · registry result, not featured evidence
5 mg
arthralgia 10.9% (placebo 1.9%)
headache 7.3% (placebo 3.7%)
hypoglycaemia 5.5% (placebo 0%)
NCT01059825 · Phase 2 · registry result, not featured evidence
25 mg
genital infection fungal 7.3% (placebo 1.9%)
diarrhoea 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
10 mg
urinary tract infection 9.1% (placebo 7.4%)
genital infection fungal 5.5% (placebo 1.9%)
upper respiratory tract infection 5.5% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
1 mg
arthralgia 3.7% (placebo 1.9%)
diarrhoea 3.7% (placebo 1.9%)
upper respiratory tract infection 3.7% (placebo 3.7%)
NCT01059825 · Phase 2 · registry result, not featured evidence
15 mg Oral + 100 ug Oral
nasal congestion 12.5%
back pain 0%
headache 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg Oral + 100 ug IV
headache 25%
back pain 12.5%
nasal congestion 0%
NCT02411929 · Phase 1 · registry result, not featured evidence · combination
15 mg
decreased appetite 12.5%
headache 12.5%
tachycardia 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
15 mg
arthralgia 12.5%
back pain 12.5%
dizziness 12.5%
NCT02115347 · Phase 1 · registry result, not featured evidence
4 mg Once Daily
diarrhoea 11.5%
headache 7.7%
abdominal pain 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Once Daily
headache 11.5%
constipation 3.8%
dizziness 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
2 mg Twice Daily
abdominal pain 3.8%
diarrhoea 3.8%
dry mouth 3.8%
NCT01054300 · Phase 1 · registry result, not featured evidence
1 mg Twice Daily
headache 12%
back pain 4%
dyspepsia 4%
NCT01054300 · Phase 1 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 24 weeks versus 4 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 24 weeks versus 26 weeks.
  7. gPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
  8. hTreatment context differs: pooled versus combination.
  9. iPopulation context differs: registered conditions differ.
  10. jAssessment timepoints differ: 4 weeks versus 12 weeks.
  11. kPopulation context differs: age eligibility differs (includes children versus adolescents and adults); baseline_threshold differs (hba1c<=10.5, hba1c>=6.5 versus none recorded); comorbidity_diabetes differs (required versus none recorded); prior_therapy differs (none recorded versus unrestricted).
  12. lPopulation comparability has not been reviewed for 31 of these studies.
  13. mPopulation comparability has not been reviewed for 44 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Empagliflozin

MACE 3-point Composite 10.4% (n=2345) vs 12.1% (n=2333) placebo10 mg
event count · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
10.5% (n=2342) vs 12.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
10.5% (n=4687) vs 12.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
MACE 4-point Composite 12.8% (n=2345) vs 14.3% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
12.8% (n=2342) vs 14.3% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
12.8% (n=4687) vs 14.3% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Silent MI 1.6% (n=1174) vs 1.2% (n=1211) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
1.6% (n=1204) vs 1.2% (n=1211) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
1.6% (n=2378) vs 1.2% (n=1211) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
HF Hospitalization 2.6% (n=2345) vs 4.1% (n=2333) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
2.8% (n=2342) vs 4.1% (n=2333) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
2.7% (n=4687) vs 4.1% (n=2333) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Albuminuria 51.5% (n=1403) vs 51.2% (n=1374) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
51.5% (n=1376) vs 51.2% (n=1374) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
51.5% (n=2779) vs 51.2% (n=1374) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
New Onset Macroalbuminuria 10.9% (n=2037) vs 16.2% (n=2033) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
11.5% (n=2054) vs 16.2% (n=2033) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
11.2% (n=4091) vs 16.2% (n=2033) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Composite Microvascular Outcome 13.9% (n=2057) vs 20.5% (n=2068) placebo10 mg
responder rate · % of participants
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
show 2 more results
14.1% (n=2075) vs 20.5% (n=2068) placebo25 mg
NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3
14% (n=4132) vs 20.5% (n=2068) placebo
NCT01131676 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Daily Plasma Glucose Change mg/dL -0.54 vs -0.11 placebo mmol/L @ 24wk10mg
absolute change · mmol/L
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -9.64 mg/dL as posted
show 5 more results
-0.56 vs -0.11 placebo mmol/L @ 24wk*10mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -10.01 mg/dL as posted
-0.8 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -14.36 mg/dL as posted
-1.97 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 · converted to mmol/L from -35.47 mg/dL as posted
-0.72 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -13.06 mg/dL as posted
-1.63 vs -0.11 placebo mmol/L @ 24wk*25mg
NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -29.34 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk10 mg, 25 mg
responder rate · % of participants
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
Time to Treatment Failure 5.5 vs 2.16 placebo months10 mg, 25 mg
time to event · months
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 · converted to months from 167.333 days as posted
Muscle Mass -1.57 vs -0.96 placebo kg @ 52wk10 mg
absolute change · kg
NCT04531462 · Phase 4 · registry result, not featured evidence
Body Fat Mass -1.77 vs 0.08 placebo kg @ 52wk10 mg
absolute change · kg
NCT04531462 · Phase 4 · registry result, not featured evidence

+ 12 further endpoints in the CSV export.

Ertugliflozin

MACE Plus 4.67 vs 4.92 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.42 vs 4.92 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Myocardial Infarction 2 vs 1.7 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
1.55 vs 1.7 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Total MACE 4.91 vs 4.59 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
4.35 vs 4.59 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
CV Death or HF Hospitalization Total 2.71 vs 3.42 placebo per 100 person year15 mg
event count · per 100 person year
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
2.92 vs 3.42 placebo per 100 person year5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
eGFR -1.81 vs -0.03 placebo mL @ 18wk15 mg
absolute change · mL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
-1.18 vs -0.3 placebo mL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.35 vs -2.6 placebo mL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.3 vs -3.8 placebo mL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.93 vs -4.41 placebo mL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.9 vs -6.8 placebo mL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.2 vs -1.8 placebo mL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.22 vs -0.03 placebo mL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.51 vs -0.3 placebo mL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.48 vs -2.6 placebo mL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.4 vs -3.8 placebo mL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.75 vs -4.41 placebo mL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.4 vs -6.8 placebo mL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.7 vs -1.8 placebo mL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
Serum Creatinine Change mg/dL 0.032 vs -0.002 placebo mg/dL @ 18wk15 mg
absolute change · mg/dL
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
0.023 vs 0.004 placebo mg/dL @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.034 placebo mg/dL @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.035 vs 0.049 placebo mg/dL @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.036 vs 0.059 placebo mg/dL @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.042 vs 0.098 placebo mg/dL @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.001 vs -0.013 placebo mg/dL @ 312wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.022 vs -0.002 placebo mg/dL @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.013 vs 0.004 placebo mg/dL @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.024 vs 0.034 placebo mg/dL @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.037 vs 0.049 placebo mg/dL @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.032 vs 0.059 placebo mg/dL @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.027 vs 0.098 placebo mg/dL @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.034 vs -0.013 placebo mg/dL @ 312wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
UACR -14.71% (n=2450) vs 0% (n=2478) placebo @ 18wk15 mg
percent change · % of baseline
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 11 more results
-6.82% (n=2277) vs 5.41% (n=2257) placebo @ 52wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.06% (n=2084) vs 17.14% (n=2025) placebo @ 104wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
3.33% (n=1915) vs 27.03% (n=1841) placebo @ 156wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
21.25% (n=835) vs 50% (n=745) placebo @ 208wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
20% (n=771) vs 48.53% (n=692) placebo @ 260wk15 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.4% (n=2472) vs 0% (n=2478) placebo @ 18wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-2.53% (n=2306) vs 5.41% (n=2257) placebo @ 52wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.73% (n=2125) vs 17.14% (n=2025) placebo @ 104wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
13.33% (n=1933) vs 27.03% (n=1841) placebo @ 156wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
33.33% (n=825) vs 50% (n=745) placebo @ 208wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
30.99% (n=780) vs 48.53% (n=692) placebo @ 260wk5 mg
NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3
PPG 2-hr Change mg/dL -3.47 vs 0.27 placebo mmol/L @ 26wk15 mg
absolute change · mmol/L
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -62.45 mg/dL as posted
show 1 more result
-3.56 vs 0.27 placebo mmol/L @ 26wk*5 mg
NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to mmol/L from -64.15 mg/dL as posted
Glycemic Rescue 1.5% (n=205) vs 17.7% (n=209) placebo @ 26wk15 mg
responder rate · % of participants
NCT02033889 · Phase 3
show 11 more results
1.5% (n=205) vs 17.2% (n=209) placebo @ 52wk15 mg
NCT02033889 · Phase 3
10.7% (n=205) vs 24.4% (n=209) placebo @ 104wk15 mg
NCT02033889 · Phase 3
2% (n=153) vs 16.3% (n=153) placebo @ 26wk15 mg
NCT02036515 · Phase 3
13.7% (n=153) vs 41.8% (n=153) placebo @ 52wk15 mg
NCT02036515 · Phase 3
0.6% (n=169) vs 9.6% (n=167) placebo @ 26wk15 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
2.9% (n=207) vs 17.7% (n=209) placebo @ 26wk5 mg
NCT02033889 · Phase 3
4.3% (n=207) vs 17.2% (n=209) placebo @ 52wk5 mg
NCT02033889 · Phase 3
11.1% (n=207) vs 24.4% (n=209) placebo @ 104wk5 mg
NCT02033889 · Phase 3
1.3% (n=156) vs 16.3% (n=153) placebo @ 26wk5 mg
NCT02036515 · Phase 3
12.8% (n=156) vs 41.8% (n=153) placebo @ 52wk5 mg
NCT02036515 · Phase 3
1.2% (n=170) vs 9.6% (n=167) placebo @ 26wk5 mg
NCT02630706 · Phase 3 · registry result, not featured evidence
Time to Rescue Therapy 4.57 vs 3.45 placebo months @ 26wk15 mg
time to event · months
NCT02033889 · Phase 3 · converted to months from 139 days as posted
show 1 more result
3.68 vs 3.45 placebo months @ 26wk*5 mg
NCT02033889 · Phase 3 · converted to months from 112 days as posted
Seated SBP -4.82 vs -0.88 placebo mmHg @ 26wk15 mg
absolute change · mmHg
Change from baseline
NCT02036515 · Phase 3
show 3 more results
-4.09 vs 0.83 placebo mmHg @ 52wk15 mg
Change from baseline
NCT02036515 · Phase 3
-3.81 vs -0.88 placebo mmHg @ 26wk5 mg
Change from baseline
NCT02036515 · Phase 3
-4.16 vs 0.83 placebo mmHg @ 52wk5 mg
Change from baseline
NCT02036515 · Phase 3
Seated DBP -1.81 vs -0.43 placebo mmHg @ 26wk15 mg
absolute change · mmHg
Change from baseline
NCT02036515 · Phase 3
show 3 more results
-1.38 vs -0.53 placebo mmHg @ 52wk15 mg
Change from baseline
NCT02036515 · Phase 3
-1.68 vs -0.43 placebo mmHg @ 26wk5 mg
Change from baseline
NCT02036515 · Phase 3
-1.52 vs -0.53 placebo mmHg @ 52wk5 mg
Change from baseline
NCT02036515 · Phase 3

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Empagliflozin's landscape · Ertugliflozin's landscape